Cantabio Pharmaceuticals Status
The company acquired Lion Consulting through a reverse merger for $38.8 million, resulting in the combined entity trading on the OTC Stock Exchange under the ticker symbol CTBO on December 17, 2015.
Developer of biotechnological therapies and intellectual property. The company focuses on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson?s disease, Alzheimer?s disease and other related neurodegenerative diseases. Its strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
Year Founded
2009
Employees
7
Net IncomeTTM 1Q2019
($21.3 K)
General Information
-
Website
-
Business Status
Pre-Clinical Trials
-
Ownership Status
Publicly Held
-
Financing Status
Corporation
Cantabio Pharmaceuticals News and Updates
Parkinson's Disease Pipeline Offers Promising New Options for Treatment | DelveInsight
GlobeNewswire | January 17, 2022
MJFF Awards Grant to Cantabio for Tau-targeting Parkinson's Therapy
Parkinson's News Today | January 6, 2022
A Special Class of Proteins Offers Promising Targets for Drugs for Cancer and Alzheimer's
Scientific American | July 1, 2019
Cantabio Pharmaceuticals's Feed
Cantabio Pharmaceuticals's Verticals
Cantabio Pharmaceuticals Primary Industry Sector / Group / Code
Cantabio Pharmaceuticals's Trends
Cantabio Pharmaceuticals Metrics
Growth Rate
Twitter Followers
Headquarters
-
HQ Address Line 12225 East Bayshore Road
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94303
-
HQ CountryUnited States
Cantabio Pharmaceuticals's Keywords
Add a review